Indeed, strategies targeting the vascular endothelial growth factor receptor 2 (VEGFR2) signaling induce vascular normalization and tumor regression in preclinical models and cancer patients when combined with other therapies such as chemo- and immuno-therapies 2, 3. Here, KDR is linked to neoplasm.